Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Celularity Inc (CELU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/19/2024: CELU (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 8.92% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/19/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.21M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 2250891 | Beta 0.76 | 52 Weeks Range 1.00 - 5.69 | Updated Date 03/30/2025 |
52 Weeks Range 1.00 - 5.69 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -100.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -72.72% | Operating Margin (TTM) -124% |
Management Effectiveness
Return on Assets (TTM) -17.45% | Return on Equity (TTM) -147.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 111139138 | Price to Sales(TTM) 0.88 |
Enterprise Value 111139138 | Price to Sales(TTM) 0.88 | ||
Enterprise Value to Revenue 2.31 | Enterprise Value to EBITDA -36.78 | Shares Outstanding 23807700 | Shares Floating 10028645 |
Shares Outstanding 23807700 | Shares Floating 10028645 | ||
Percent Insiders 56.26 | Percent Institutions 15.01 |
Analyst Ratings
Rating 4 | Target Price 2.5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was founded in 2016 as a spin-off from Celgene (now part of Bristol Myers Squibb) focusing on cellular medicine. It went public in 2021 through a SPAC merger. The company leverages placental-derived cells and biomaterials to develop allogeneic cell therapies and advanced biomaterials.
Core Business Areas
- Cellular Medicine: Development of allogeneic cell therapies derived from the placenta to treat diseases across oncology, infectious diseases, and degenerative diseases.
- Advanced Biomaterials: Development and commercialization of biomaterials derived from the placenta for surgical and wound care applications.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The company has a board of directors that oversees the strategic direction and governance of the organization.
Top Products and Market Share
Key Offerings
- Competitors: Gilead Sciences (GILD), Regeneron (REGN), Athersys (ATHX)
- PDA-002: An investigational cryopreserved human placental hematopoietic stem cell-derived therapy for COVID-19 related ARDS. Market share and revenue are not yet established as it is still in clinical trials. Competitors include established pharmaceutical companies with antiviral therapies and other cell therapy developers.
- CYNK-001: An off-the-shelf natural killer (NK) cell therapy designed to target various cancers. Market share and revenue are not yet established as it is still in clinical trials. Competitors include other NK cell therapy developers.
- Competitors: NantKwest (NK), Fate Therapeutics (FATE), Affimed (AFMD)
- Biomaterials portfolio: A line of biomaterial products utilized in surgical and advanced wound care procedures. Includes products such as Intercyteu2122 and BioLocku2122. Revenue contribution and market share not yet available. Competitors include companies like Integra LifeSciences (IART) and Organogenesis (ORGO).
- Competitors: Integra LifeSciences (IART), Organogenesis (ORGO)
Market Dynamics
Industry Overview
The cellular medicine and biomaterials industry is experiencing rapid growth, driven by advancements in biotechnology and increasing demand for novel therapies and regenerative solutions.
Positioning
Celularity is positioned as a leader in placental-derived cellular therapies and biomaterials, leveraging its proprietary platform and intellectual property. It aims to address unmet needs in oncology, infectious diseases, and degenerative diseases.
Total Addressable Market (TAM)
The TAM for cellular therapies and biomaterials is estimated to be billions of dollars. Celularity is positioned to capture a share of this market through its innovative products and technologies.
Upturn SWOT Analysis
Strengths
- Proprietary placental-derived cell therapy platform
- Experienced management team
- Strong intellectual property portfolio
- Potential for off-the-shelf cell therapies
- Diversified product pipeline
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- Significant cash burn
- Competition from established pharmaceutical companies
- Dependence on strategic partnerships
Opportunities
- Expansion of product pipeline through research and development
- Strategic partnerships and collaborations
- Regulatory approvals for key product candidates
- Market growth in cellular therapies and biomaterials
- Acquisition opportunities
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cell therapy developers
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- Fate Therapeutics (FATE)
- Organogenesis (ORGO)
- Integra Lifesciences (IART)
Competitive Landscape
Celularity faces competition from established pharmaceutical companies and other cell therapy developers. Its competitive advantage lies in its placental-derived cell therapy platform and diversified product pipeline. Its lack of established products poses a disadvantage.
Major Acquisitions
CD34+
- Year: 2018
- Acquisition Price (USD millions): 15
- Strategic Rationale: Expanded Celularity's intellectual property and product portfolio in cell therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's relatively recent founding and focus on research and development.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates. Analyst estimates vary widely, reflecting the uncertainty of the biotechnology industry.
Recent Initiatives: Recent initiatives include advancing clinical trials for PDA-002 and CYNK-001, expanding its biomaterials portfolio, and seeking strategic partnerships.
Summary
Celularity is a relatively young biotechnology company with a unique placental-derived cell therapy platform and diversified product pipeline. The company has the potential to disrupt the cellular medicine and biomaterials industries but faces significant challenges, including clinical trial risks, regulatory hurdles, and intense competition. Its long-term success depends on its ability to successfully develop and commercialize its product candidates. While innovative, it faces a substantial cash burn and reliance on clinical trial outcomes.
Similar Companies
- MESO
- CRIS
- VCEL
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data provided is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-08-08 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 120 | Website https://www.celularity.com |
Full time employees 120 | Website https://www.celularity.com | ||
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates; and a collaboration agreement with BlueSphere Bio, Inc. covering manufacturing activities for certain cell therapy products. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.